Literature DB >> 20448484

Partial depletion of CREB-binding protein reduces life expectancy in a mouse model of Huntington disease.

Alexandra M Klevytska1, Andrew T N Tebbenkamp, Alena V Savonenko, David R Borchelt.   

Abstract

Previous studies have reported that mutant huntingtin (htt) interferes with cyclic AMP response element binding protein binding protein (CBP)-mediated transcription, possibly by inhibiting the acetylation of histones. In Drosophila models that express fragments of mutant htt, histone deacetylase inhibitors reverse deficits in histone acetylation, rescue photoreceptor degeneration, and prolong their survival. These compounds also improve motor deficits in a transgenic mouse model of Huntington disease (HD). To determine whether endogenous CBP depletion contributes to HD pathogenesis, we crossed HD-N171-82Q transgenic mice with mice harboring a disrupted CBP gene and produced mice with partial (50%) depletion of CBP. This reduction of CBP levels decreased the life expectancy of the HD-N171-82Q Line 6 mouse model. The loss of CBP had no obvious impact on the severity of motor impairment, degeneration of the striatum, mutant htt inclusion formation, or global levels of acetylated histones H3 or H4 in brain. In cell models, we confirmed that mutant htt inclusions recruit human CBP but found no evidence for interactions between soluble forms of mutant htt and CBP. Although we identified no neurological explanation for the decreased life expectancy of HD-N171-82Q mice with partial depletion of CBP, the data are consistent with the notion that CBP function mitigates mutant htt toxicity by a currently unidentified mechanism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20448484     DOI: 10.1097/NEN.0b013e3181d6c436

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  12 in total

1.  Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT.

Authors:  Cesar L Moreno; Michelle E Ehrlich; Charles V Mobbs
Journal:  Neurobiol Dis       Date:  2015-10-17       Impact factor: 5.996

Review 2.  The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease.

Authors:  Ignacio Munoz-Sanjuan; Gillian P Bates
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

Review 3.  Acetyltransferases (HATs) as targets for neurological therapeutics.

Authors:  Anne Schneider; Snehajyoti Chatterjee; Olivier Bousiges; B Ruthrotha Selvi; Amrutha Swaminathan; Raphaelle Cassel; Frédéric Blanc; Tapas K Kundu; Anne-Laurence Boutillier
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

4.  Potential role of TrkB agonist in neuronal survival by promoting CREB/BDNF and PI3K/Akt signaling in vitro and in vivo model of 3-nitropropionic acid (3-NP)-induced neuronal death.

Authors:  Sahabuddin Ahmed; Mohit Kwatra; Basveshwar Gawali; Samir Ranjan Panda; V G M Naidu
Journal:  Apoptosis       Date:  2020-11-23       Impact factor: 4.677

5.  Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease.

Authors:  Rajnish Kumar Chaturvedi; Thomas Hennessey; Ashu Johri; Shashi Kant Tiwari; Divya Mishra; Swati Agarwal; Yoon Seong Kim; M Flint Beal
Journal:  Hum Mol Genet       Date:  2012-05-15       Impact factor: 6.150

Review 6.  Epigenetic memory: the Lamarckian brain.

Authors:  Andre Fischer
Journal:  EMBO J       Date:  2014-04-09       Impact factor: 11.598

Review 7.  Epigenetic Changes in Neurodegenerative Diseases.

Authors:  Min Jee Kwon; Sunhong Kim; Myeong Hoon Han; Sung Bae Lee
Journal:  Mol Cells       Date:  2016-11-18       Impact factor: 5.034

Review 8.  Polyglutamine (polyQ) disorders: the chromatin connection.

Authors:  Dorit Cohen-Carmon; Eran Meshorer
Journal:  Nucleus       Date:  2012-08-15       Impact factor: 4.197

Review 9.  Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders.

Authors:  Luis M Valor; Jose Viosca; Jose P Lopez-Atalaya; Angel Barco
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

10.  Epigenetics-beyond the genome in alcoholism.

Authors:  Bela G Starkman; Amul J Sakharkar; Subhash C Pandey
Journal:  Alcohol Res       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.